1.	Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670ADE03, NCT00481143
2.	Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Phase: Phase IV Type: Supportive care Status: Completed Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670AHU02, NCT00564941
3.	Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Phase: Phase IV Type: Diagnostic, Supportive care Status: Completed Age: 16 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670AAU01, NCT00673608
4.	Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670A2417, 2011-001077-13, NCT01326845
5.	A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 2 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670A2409, 2004-003953-16, NCT00171821
6.	Safety, Tolerability, and Efficacy of Deferasirox in MDS Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: MDS0306, NCT00469560
7.	Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670AUS02, NCT00117507
8.	Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670AUS03, UCLA-0508054-01, NOVARTIS-CICL670AUS03, NCT00110266
9.	Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload Phase: Phase II Type: Supportive care Status: Closed Age: 10 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CICL670A2206, 2007-000766-20, NCT00600938
10.	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CCCWFU 97710, NCI-2010-02228, NCT01273766